Evidence map›Paper›PMID 41993550›Full record

ArticlebioRxiv : the preprint server for biology2026

Fatty acid biosynthesis inhibitors fabimycin and triclosan trigger distinct resistance mutations in FabI and potently kill Gram-negative pathogens.

Brett N Cain, James E Kent, Marinela Elane, John D Williams, Myung Ryul Lee, Gee W Lau, Paul J Hergenrother, Andrei L Osterman

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Brett N CainDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
James E KentSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 920376, USA.ORCID 0000-0002-4856-525X
Marinela ElaneSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 920376, USA.
John D WilliamsWalter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA.
Myung Ryul LeeDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
Gee W LauDepartment of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
Paul J HergenrotherDepartment of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
Andrei L OstermanSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 920376, USA.ORCID 0000-0002-3810-9824

Funding

FabI Inhibitors as Potent, Gut Microbiome-Sparing AntibioticsR01AI176523 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Paul Hergenrother · 2023 to 2026
$3.9M
Comparative resistomics of Gram-negative bacterial pathogensR01AI167977 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ANDREI L OSTERMAN · 2022 to 2026
$3.7M
NIAID NIH HHS R01 AI167977NIAID NIH HHS R01 AI176523
6 · The paper itself

Abstract

In the effort to develop efficacious antibacterials that engage targets for which there is no pre-existing resistance, inhibition of the enoyl-acyl carrier protein reductase FabI has shown promise, with triclosan and fabimycin as representative members of the two major drug classes that show activity against important bacterial pathogens. Here, we use a morbidostat and whole genome sequencing to comprehensively evaluate the resistance profiles that arise in pathogenic bacteria in response to these FabI inhibitors. When assessed against

Identifiers

PMID41993550
PMCPMC13082018

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.